The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis

Table 2 Subgroup analysis of the grade 3 or higher adverse events

Experimental vs. control	No. of studies	RR	95% CI	p	Heterogeneity
Experimental vs. control	No. of studies	RR	95% CI	p	(I²) (%)
Grade 3 or higher adverse events	8	1.87	1.27–2.77	0.002	96
Grade 3 or higher abdominal pain	9	1.08	0.69–1.68	0.74	0
Grade 3 or higher anemia	10	9.94	2.63–37.50	< 0.001	92
Grade 3 or higher arthralgia	7	0.81	0.32–2.03	0.66	0
Grade 3 or higher constipation	9	0.92	0.31–2.72	0.88	16
Grade 3 or higher decreased appetite	6	2.39	0.76–7.52	0.14	0
Grade 3 or higher diarrhea	8	0.92	0.53–1.59	0.75	0
Grade 3 or higher dizziness	6	0.85	0.12–5.99	0.87	36
Grade 3 or higher fatigue	10	2.39	1.67–3.44	< 0.001	0
Grade 3 or higher headache	8	0.55	0.22–1.37	0.20	0
Grade 3 or higher nausea	9	2.57	1.57–4.22	< 0.001	0
Grade 3 or higher neutropenia	9	2.42	1.41–4.17	0.001	81
Grade 3 or higher thrombocytopenia	8	4.66	1.26–17.19	0.02	84
Grade 3 or higher vomiting	9	1.43	0.86–2.37	0.17	0

ISSN: 1477-7819